Pyrazole–triazole hybrids as kinase-triad inhibitors: a triple-target strategy for synergistic anticancer therapy

RSC Medicinal Chemistry 2026 Open access

Read full text
Authors: Mahmoud S. Elkotamy, Mohamed K. Elgohary, Mariam M. Fakhry, Mohamed E. Albakri, Abdelrahman A. Naglah, Abdelrahman A. Naglah, Abdulrahman A. Almehizia, Ahmed M. Naglah, Ahmed M. Naglah, Mohamed Fares, Haytham O. Tawfik, Wagdy M. Eldehna
+1 more Hatem A. Abdel-Aziz
DOI: 10.1039/d6md00022c
Cited by: 3
References: 92

Abstract

ADME profiling indicated favorable drug-likeness, especially for series 7. These findings identify compounds 7i and 10a as potential dual-scaffold leads for subsequent preclinical development as multi-target anticancer agents.

Fields of Study & Subjects

Click Chemistry and Applications Synthesis and biological activity Synthesis and Reactivity of Heterocycles

Publication details

Journal / source
RSC Medicinal Chemistry
Publisher
Royal Society of Chemistry (RSC)
Volume
17
Issue
5
Pages
2360–2386
Publication date
1 January 2026
Language
EN